Aqua Medical Highlights 100% Insulin Elimination for 12 Months in Patients with Type 2 Diabetes with its Breakthrough “Through-the-Scope” Procedure at Digestive Disease Week® (DDW) 2026

PLEASANTON, Calif., May 5, 2026 /PRNewswire/ — Aqua Medical, Inc., a pioneer in Endoscopic Metabolic Restoration (www.aquaendoscopy.com), yesterday announced the presentation of 12-month follow-up outside US clinical data for its proprietary radiofrequency vapor ablation (RFVA) platform at Digestive Disease Week® (DDW) 2026, highlighting the potential of its Proximal Intestinal Mucosal Ablation (PIMA) procedure to deliver durable, procedure-based treatment for type 2 diabetes. Data presented at DDW […]

Aqua Medical Secures FDA IDE to Study its Breakthrough Endoscopic Technology for the treatment of Type 2 Diabetes

PLEASANTON, Calif., Nov. 4, 2025 /PRNewswire/ — Aqua Medical, a company advancing Endoscopic Metabolic Restoration for type 2 diabetes, today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval for its pilot clinical trial of the Proximal Intestinal Mucosal Ablation (PIMA) procedure using the company’s proprietary radiofrequency vapor ablation (RFVA) […]